Cancer

StrainsForPains, Inc. Discusses Inspiration, App Technology and CBD Market Entrance with The Stock Day Podcast

Retrieved on: 
Thursday, February 29, 2024

I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.

Key Points: 
  • I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.
  • I developed regenerative medicine systems with stem cell technology in the 1980's working on umbilical cord therapy to treat genetic diseases, cancers, and inherited disorders.
  • In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products.
  • We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app.

Kidney Foundation Marks 60th Anniversary

Retrieved on: 
Thursday, February 29, 2024

Learn more during Kidney Health Month in March

Key Points: 
  • Montreal, Quebec--(Newsfile Corp. - February 29, 2024) - When the Kidney Foundation of Canada was launched in 1964, a person with kidney failure had very little hope of survival.
  • As we work to raise awareness of these vital organs, The Kidney Foundation is reflecting on the significant progress made in the past six decades to improve the quality of life and health outcomes of kidney patients.
  • "These advances are providing new hope for people diagnosed with kidney disease and those living with kidney failure."
  • The Kidney Foundation is ramping up advocacy efforts to ensure that every Canadian has access to the care they need to prevent or delay the progression of kidney disease.

ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update

Retrieved on: 
Tuesday, February 27, 2024

The Company confirms that the Offering Price was reserved confidentially on January 31, 2024 pursuant to section 6.2(4) of Policy 6 of the Canadian Securities Exchange (the "Exchange").

Key Points: 
  • The Company confirms that the Offering Price was reserved confidentially on January 31, 2024 pursuant to section 6.2(4) of Policy 6 of the Canadian Securities Exchange (the "Exchange").
  • Each Unit will be comprised of one common share of the Company (each, a "Share") and one Share purchase warrant (each, a "Warrant").
  • Completion of the Offering remains subject to certain conditions, including confirmation of no objection from the Exchange.
  • The Company continues to pursue research and development of its G-CSF antibody candidate, myeloid prodrug candidate and novel LNP formulation as previously disclosed in the Company's corporate update news release dated January 25, 2024.

Pacylex to Meet with Investors at Bio CEO Conference (BCIC) in New York City, February 26-27, 2024

Retrieved on: 
Friday, February 23, 2024

The company's lead candidate, zelenirstat, is a first-in-class, orally bioavailable small molecule myristoylation inhibitor, a new mechanism of action for cancer treatment.

Key Points: 
  • The company's lead candidate, zelenirstat, is a first-in-class, orally bioavailable small molecule myristoylation inhibitor, a new mechanism of action for cancer treatment.
  • Zelenirstat is currently being studied in patients who have failed available treatments (refractory or relapsed; r/r).
  • If you are attending BIO CEO & Investors, we would like to talk to you about investing in Pacylex and zelenirstat, a first-in-class oral cancer drug in Phase 2.
  • Zelenirstat has a great safety profile and evidence of benefit in refractory patients with solid and liquid tumors.

Pattern to Attend NVIDIA’s GTC 2024 Conference

Retrieved on: 
Monday, March 11, 2024

REDMOND, Wash., March 11, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will attend NVIDIA’s GTC 2024 Conference.

Key Points: 
  • REDMOND, Wash., March 11, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will attend NVIDIA’s GTC 2024 Conference.
  • During the conference, Pattern will conduct one-on-one meetings with investors and potential partners, showcasing the Company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
  • To schedule a meeting with Pattern, please contact Pattern’s Executive Vice President of Special Projects, Denyse Hudson, at [email protected] .
  • Mr. Anderson commented, “Pattern uses proprietary pattern discovery techniques to perform high-dimensional data analytics in any field with significant data complexity.

HIMALAYA TECHNOLOGIES PARTNERS WITH RENOVI! TO TARGET MEDICAL TOURISM MARKET IN CARIBBEAN; ADDS CEO TO ADVISORY BOARD

Retrieved on: 
Monday, March 11, 2024

Additionally, the Company has appointed Renovi!’s CEO, David Burns, Ph.D., to its Advisory Board to guide its entry into this multi-billion dollar market, assist on mergers and acquisitions including a potential combination of Renovi!

Key Points: 
  • Additionally, the Company has appointed Renovi!’s CEO, David Burns, Ph.D., to its Advisory Board to guide its entry into this multi-billion dollar market, assist on mergers and acquisitions including a potential combination of Renovi!
  • The availability of the newest medical technologies and the cheaper cost of treatment in emerging nations are key market drivers enhancing market growth.
  • reinvents traditional outpatient rehabilitation by offering patients a “recovery vacation” at an upscale, beachfront medical resort with healthy diet, exercise, community and exceptional medical care.
  • The Dominican Republic is uniquely positioned as a medical tourism destination because of its low costs, proximity to the U.S., a well-established tourism infrastructure, and tax incentives for tourism investments.

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 11, 2024

“In 2023 we demonstrated the unique opportunity ahead for palazestrant to make a meaningful impact on improving treatment options for women with ER+/HER2- breast cancer.

Key Points: 
  • “In 2023 we demonstrated the unique opportunity ahead for palazestrant to make a meaningful impact on improving treatment options for women with ER+/HER2- breast cancer.
  • Presented palazestrant monotherapy Phase 2 clinical results at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, as an oral presentation demonstrating compelling activity in both wild-type and ESR1-mutant tumor types.
  • Non-GAAP G&A expenses were $3.1 million and $13.3 million for the quarter and year ended December 31, 2023, respectively, excluding $1.4 million and $5.5 million non-cash stock-based compensation expense respectively.
  • A reconciliation of GAAP to non-GAAP financial measures used in this press release can be found at the end of this press release.

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, March 11, 2024

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
  • Research and development expenses were $40.5 million for the year ended December 31, 2023, compared to $62.5 million for 2022.
  • 2023 and Recent Corporate Highlights:
    In July 2023, Mustang announced that it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc. (“uBriGene”) and closed the transaction.
  • In October 2023, Mustang completed a registered direct offering priced at-the-market for approximately $4.4 million in gross proceeds.

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024

SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update.

Key Points: 
  • Throughout 2023, CytomX made substantial progress across all research partnerships including the commencement of programs under its new alliances with Regeneron and Moderna.
  • In 2023, CytomX remained focused on controlling costs and efficiently allocating capital towards its lead pipeline programs.
  • General and administrative expenses in the fourth quarter of 2023 were $7.8 million compared to $10.1 million in the corresponding period in 2022.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE

Retrieved on: 
Monday, March 11, 2024

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.